Significance of miRNA-122 in chronic hepatitis C patients with serotype 1 on interferon therapy

Hepatology Research

Volumn 45, Issue 1, 2015, Pages 88-96

  Kamo, Yasuhiro ^a   Ichikawa, Tatsuki ^a   Miyaaki, Hisamitsu ^a   Uchida, Shinjirou ^a   Yamaguchi, Tohei ^a   Shibata, Hidetaka ^a   Honda, Takuya ^a   Taura, Naota ^a   Isomoto, Hajime ^a   Takeshima, Fuminao ^a   Nakao, Kazuhiko ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

Chronic hepatitis C; Interferon; MiRNA 122

Indexed keywords

CHOLESTEROL; INTERFERON; LIPID; MICRORNA 122; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; FEMALE; GENE; GENE EXPRESSION; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IL28B GENE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONHUMAN; PRIORITY JOURNAL; RNA REPLICATION; SEROTYPE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84921031226     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12317     Document Type: Article

References (38)

1. Ascione A, Tartaglione T, Di Costanzo GG. Natural history of chronic hepatitis C virus infection. Dig Liver Dis 2007; 39 (Suppl 1): S4-7.
2. Bruno S, Facciotto C. The natural course of HCV infection and the need for treatment. Ann Hepatol 2008; 7: 114-119.
3. Forestier N, Zeuzem S. Telaprevir for the treatment of hepatitis C. Expert Opin Pharmacother 2012; 13: 593-606.
4. Vachon ML, Dieterich DT. The era of direct-acting antivirals has begun: the beginning of the end for HCV? Semin Liver Dis 2011; 31: 399-409.
5. Quer J, Buti M, Cubero M, Guardia J, Esteban R, Esteban JI. New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents. Infect Drug Resist 2010; 3: 133-145.
6. Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012; 56 (Suppl 1): S88-100.
7. Asselah T, Marcellin P. New direct-acting antivirals' combination for the treatment of chronic hepatitis C. Liver Int 2011; 31 (Suppl 1): 68-77.
8. Mira JA, Valera-Bestard B, Arizcorreta-Yarza A etal. Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients. Antivir Ther 2007; 12: 523-529.
9. Shirakawa H, Matsumoto A, Joshita S etal. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 2008; 48: 1753-1760.
10. Asselah T, Estrabaud E, Bieche I etal. Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int 2010; 30: 1259-1269.
11. Harrison SA, Rossaro L, Hu KQ etal. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology 2010; 52: 864-874.
12. Kitamura S, Tsuge M, Hatakeyama T etal. Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy. Antivir Ther 2010; 15: 1087-1097.
13. Kurosaki M, Tanaka Y, Nishida N etal. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol 2011; 54: 439-448.
14. Tanaka Y, Nishida N, Sugiyama M etal. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
15. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004; 5: 522-531.
16. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
17. Ambros V. The functions of animal microRNAs. Nature 2004; 431: 350-355.
18. Shen J, Cho CH. miRNA in the pathogenesis and Therapy for Gastrointestinal and Hepatic Cancer. Curr Pharm Des 2013; 19: 1179.
19. Jopling CL, Norman KL, Sarnow P. Positive and negative modulation of viral and cellular mRNAs by liver-specific microRNA miR-122. Cold Spring Harb Symp Quant Biol 2006; 71: 369-376.
20. Roberts AP, Lewis AP, Jopling CL. miR-122 activates hepatitis C virus translation by a specialized mechanism requiring particular RNA components. Nucleic Acids Res 2011; 39: 7716-7729.
21. Jangra RK, Yi M, Lemon SM. Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122. J Virol 2010; 84: 6615-6625.
22. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005; 309: 1577-1581.
23. Henke JI, Goergen D, Zheng J etal. microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J 2008; 27: 3300-3310.
24. Lanford RE, Hildebrandt-Eriksen ES, Petri A etal. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327: 198-201.
25. Stenvang J, Petri A, Lindow M, Obad S, Kauppinen S. Inhibition of microRNA function by antimiR oligonucleotides. Silence 2012; 3: 1.
26. Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med 2009; 15: 31-33.
27. Watashi K, Ishii N, Hijikata M etal. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 2005; 19: 111-122.
28. Okamoto T, Nishimura Y, Ichimura T etal. Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90. EMBO J 2006; 25: 5015-5025.
29. Parent R, Qu X, Petit MA, Beretta L. The heat shock cognate protein 70 is associated with hepatitis C virus particles and modulates virus infectivity. Hepatology 2009; 49: 1798-1809.
30. Wang C, Gale M, Keller BC etal. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Mol Cell 2005; 18: 425-434.
31. Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci U S A 2005; 102: 2561-2566.
32. Yang W, Hood BL, Chadwick SL etal. Fatty acid synthase is up-regulated during hepatitis C virus infection and regulates hepatitis C virus entry and production. Hepatology 2008; 48: 1396-1403.
33. Herker E, Ott M. Unique ties between hepatitis C virus replication and intracellular lipids. Trends Endocrinol Metab 2011; 22: 241-248.
34. Miyanari Y, Atsuzawa K, Usuda N etal. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 2007; 9: 1089-1097.
35. Castoldi M, Vujic Spasic M, Altamura S etal. The liver-specific microRNA miR-122 controls systemic iron homeostasis in mice. J Clin Invest 2011; 121: 1386-1396.
36. Moore KJ, Rayner KJ, Suárez Y, Fernández-Hernando C. The role of microRNAs in cholesterol efflux and hepatic lipid metabolism. Annu Rev Nutr 2011; 31: 49-63.
37. Rottiers V, Näär AM. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol 2012; 13: 239-250.
38. Cheung O, Puri P, Eicken C etal. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 2008; 48: 1810-1820.